Clinical Trial Update: PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating PRT3789 as monotherapy or in combination with docetaxel in SMARCA4-mutant advanced/metastatic solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• PRT3789

Snippet

Sponsor: Prelude Therapeutics | Conditions: Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Status: COMPLETED